Not medical advice. GHRP-2 is a research compound. This guide does not provide dosing, diagnosis, therapy recommendations, or claims about effects in humans.
GHRP-2 (pralmorelin) is a high-affinity ghrelin receptor agonist and the first growth hormone secretagogue to reach clinical approval as a diagnostic agent for growth hormone deficiency in Japan.
One-paragraph overview from our research datasheet — still scientific, but faster to read than the full mechanism list below.
GHRP-2 (Pralmorelin), potent hexapeptide GHS-R1a agonist and first clinically approved growth hormone secretagogue for GHD diagnostic applications.
Peer-reviewed literature typically discusses GHRP-2 in specific experimental settings. The points below reflect how the scientific community frames this compound—not as health claims, but as the research questions being asked.
Research vs. personal use: Literature describes experiments in controlled lab and animal models. This is distinct from any real-world use; our products are for laboratory research only.
Growth-hormone axis peptides are researched for how they signal through the GH/IGF pathway in animals and cells. Studies focus on endocrine biology and metabolism, not on prescribing or outcomes in people.
Our datasheet lists mechanistic themes observed in preclinical work. These are research endpoints, not health claims. They help scientists understand and compare pathways.
Storage requirements: Lyophilised powder: store in freezer (−20 °C). Reconstituted: refrigerate 1–6 °C, away from sunlight. Use within the validated stability window for the specific batch and formulation. · Learn best practices in our detailed storage guide.
Research dosing context: Literature typically discusses 100–300 mcg subcutaneously · 2–3 times daily · Functional t½ ≈ 15–30 min; peak GH at ~15 min post-administration; GH elevation persists ~60 min; oral bioavailability demonstrated but low (~0.3%); approved diagnostic dose: 100 mcg IV (GHRP Kaken 100). Rapid degradation in vivo, multiple daily administrations required for sustained effects.
Preparation steps: Follow our detailed reconstitution guide, use the calculator tool for volume confirmation, and always verify purity with the COA reading guide.
GHRP-2 (pralmorelin) is a synthetic six-amino-acid growth hormone secretagogue that binds the ghrelin receptor (GHS-R1a) on the pituitary to trigger a sharp pulse of the body's own growth hormone. It is the first GH secretagogue to gain any regulatory approval, used as a GH-deficiency diagnostic in Japan. Supplied here as a lyophilised research-grade powder for laboratory use only.
Both are hexapeptide ghrelin-receptor agonists, but GHRP-2 releases more growth hormone per dose while producing a milder appetite (orexigenic) effect. GHRP-6 is the original of the family and the strongest hunger stimulant. Researchers reach for GHRP-2 when they want GH output without the pronounced appetite signal of GHRP-6.
GHRP-2 is a stronger GH releaser per dose, but it also produces modest cortisol, ACTH, and prolactin elevation that ipamorelin does not. Ipamorelin is cleaner and more selective; GHRP-2 is more potent and has a richer clinical pharmacokinetic dataset. The choice depends on whether the research protocol prioritises selectivity or potency.
GHRP-2 is short-acting, with a functional half-life on the order of 15-30 minutes. The growth-hormone pulse it triggers typically peaks around 15 minutes after subcutaneous administration and returns toward baseline within roughly an hour, which is why research protocols describe multiple separated doses rather than a single sustained one.
Moderately. GHRP-2 activates hypothalamic ghrelin receptors enough to produce a noticeable increase in hunger in research subjects, but less dramatically than GHRP-6, which is the strongest orexigenic member of the family. The appetite effect is a direct consequence of acting on the same receptor as natural ghrelin.
GHRP-2 and CJC-1295 (a GHRH analogue) act on two different receptors - the ghrelin receptor and the GHRH receptor - that converge on growth-hormone release. Combining them in research models produces a larger, cleaner GH pulse than either peptide alone, which is the standard rationale for pairing a GHRP with a GHRH analogue.
Oral bioactivity has been demonstrated across multiple species, though absolute oral bioavailability is quite low (roughly 0.3%). That means meaningful oral exposure requires much larger amounts than subcutaneous or IV, but the route does function in research protocols, and intranasal delivery has also been validated.
Keep the lyophilised powder frozen at −20 °C. After reconstitution with bacteriostatic water, refrigerate at 1-6 °C and protect from light. GHRP-2 is reasonably stable in solution within the standard peptide-handling window.
No, and no. This article is educational only. We do not provide dosing, medical recommendations, or health claims. Our products are sold strictly for laboratory research, not for personal use of any kind.
Open the shop listing via “View product details.” There you will see batch specs, the Certificate of Analysis (COA), concentration, purity grade, and available SKUs with current pricing.
Other compounds researchers often read about alongside GHRP-2.
Primary literature and registries for GHRP-2, plus mainstream coverage of the peptide category. Research use only - not medical advice.
Databases & literature:
Peptides in the news:
Access concentration, batch info, variants, and current pricing on our shop.
Also known as: Pralmorelin, KP-102, GPA-748, Growth Hormone Releasing Peptide-2, GHRP Kaken 100, Pralmorelin Hydrochloride, Pralmorelin Dihydrochloride